Infections in vasculitis

被引:39
作者
Guillevin, Loic [1 ]
机构
[1] Univ Paris 05, Hop Cochin, Assistance Publ Hop Paris, Dept Internal Med, F-75679 Paris, France
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2013年 / 27卷 / 01期
关键词
Vasculitis; Infections; Vaccination; Prophylaxis; HEPATITIS-B-VIRUS; CHURG-STRAUSS-SYNDROME; PNEUMOCYSTIS-CARINII-PNEUMONIA; MIXED CRYOGLOBULINEMIA VASCULITIS; TERM-FOLLOW-UP; POLYARTERITIS-NODOSA; RANDOMIZED-TRIAL; MICROSCOPIC POLYANGIITIS; WEGENERS-GRANULOMATOSIS; EXTRAHEPATIC MANIFESTATIONS;
D O I
10.1016/j.berh.2013.01.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Infections, mainly viral, are the cause of some vasculitides, like polyarteritis nodosa (hepatitis B virus) or mixed cryoglobulinemia (hepatitis C virus), and it has been hypothesized that others might be due to infectious agents (HIV, EBV, parvovirus...). Among etiologies of vasculitis, the responsibility of a Burkholderia-like strain has been recently demonstrated as the cause of giant-cell arteritis. On the other hand, patients frequently develop infections, mainly as a consequence of steroids, immunosuppressants and most immunomodulating treatments prescribed to treat vasculitides. Infections occur when patients receive steroids and immunosuppressants, especially in the long term. They are more frequently observed in elderly patients or in patients with poor general condition. Infection risk is not reduced when biotherapies are prescribed to induce or maintain remission. Patients, considered at higher risk for infections, should be followed closely and their immunological status monitored periodically. We recommend especially to monitor neutrophiles, lymphocytes and if needed CD3-, CD4- and CD8-cell counts in patients receiving steroids and cyclophosphamide or other cytotoxic agents. In patients treated with rituximab, CD19 and gammaglobulins should be monitored regularly. Prophylaxis are needed in patients at risk to develop infections. (C) 2013 Published by Elsevier Ltd.
引用
收藏
页码:19 / 31
页数:13
相关论文
共 90 条
[31]   Hepatitis B virus-associated polyarteritis Nodosa - Clinical characteristics, outcome, and impact of treatment in 115 patients [J].
Guillevin, L ;
Mahr, A ;
Callard, P ;
Godmer, P ;
Pagnoux, C ;
Leray, E ;
Cohen, P .
MEDICINE, 2005, 84 (05) :313-322
[32]   Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus - Related polyarteritis nodosa [J].
Guillevin, L ;
Mahr, A ;
Cohen, P ;
Larroche, C ;
Queyrel, V ;
Loustaud-Ratti, V ;
Imbert, B ;
Hausfater, P ;
Roudier, J ;
Bielefeld, P ;
Petitjean, P ;
Smadja, D .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (03) :482-487
[33]  
GUILLEVIN L, 1988, BRIT J RHEUMATOL, V27, P258
[34]  
GUILLEVIN L, 1991, J RHEUMATOL, V18, P567
[35]   A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis [J].
Guillevin, L ;
Cordier, JF ;
Lhote, F ;
Cohen, P ;
Jarrousse, B ;
Royer, I ;
Lesavre, P ;
Jacquot, C ;
Bindi, P ;
Bielefeld, P ;
Desson, JF ;
Détrée, F ;
Dubois, A ;
Hachulla, E ;
Hoen, B ;
Jacomy, D ;
Seigneuric, C ;
Lauque, D ;
Stern, M ;
Longy-Boursier, M .
ARTHRITIS AND RHEUMATISM, 1997, 40 (12) :2187-2198
[36]   Vasculitides in the context of HIV infection [J].
Guillevin, Loic .
AIDS, 2008, 22 :S27-S33
[37]  
Guillevin L, 2012, ARTHRITIS RHEUM-US, V64, pS706
[38]   How to treat systemic necrotizing vasculitides? [J].
Guillevin, Loic .
PRESSE MEDICALE, 2012, 41 (10) :1024-1030
[39]   The Five-Factor Score Revisited Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort [J].
Guillevin, Loic ;
Pagnoux, Christian ;
Seror, Raphaele ;
Mahr, Alfred ;
Mouthon, Luc ;
Le Toumelin, Philippe .
MEDICINE, 2011, 90 (01) :19-27
[40]   WEGENER GRANULOMATOSIS - AN ANALYSIS OF 158 PATIENTS [J].
HOFFMAN, GS ;
KERR, GS ;
LEAVITT, RY ;
HALLAHAN, CW ;
LEBOVICS, RS ;
TRAVIS, WD ;
ROTTEM, M ;
FAUCI, AS .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (06) :488-498